Telix Pharmaceuticals (NASDAQ: TLX) announced the publication of results from its ProstACT SELECT Phase 1 study in Cancers, a peer-reviewed journal, according to a company statement.

The study evaluated TLX591-Tx (lutetium-177 rosopatamab tetraxetan), a prostate-specific membrane antigen (PSMA)-targeting radio antibody-drug conjugate therapy candidate for advanced metastatic castration-resistant prostate cancer (mCRPC). The primary objective was to assess whether gallium-68 PSMA-PET imaging could identify patients suitable for TLX591-Tx therapy using a theranostic approach.

The publication reports a median radiographic progression-free survival of 8.8 months in evaluable patients receiving TLX591-Tx in combination with standard of care. The authors noted the therapy demonstrated a manageable and predictable safety profile in a patient population described as representative of a real-world setting. The study also highlighted prolonged tumor retention and low salivary gland irradiation.

Nat Lenzo, principal investigator on the study, said the results "clearly support" using PSMA-PET imaging to select patients for TLX591-Tx therapy and that the data provides "compelling evidence" that the imaging agent and TLX591-Tx target the same disease sites.

TLX591-Tx has not received marketing authorization in any jurisdiction. Telix is currently evaluating the therapy in the ProstACT Global Phase 3 international multi-center study for mCRPC.